SB 422 requires Montana health insurers to cover FDA-approved drugs for advanced or metastatic cancer without forcing patients to first fail other treatments. It prohibits insurers from demanding that patients prove they've tried and failed alternative drugs before approving coverage for new treatments that align with national cancer guidelines. This directly affects patients diagnosed with advanced or metastatic cancer in Montana, ensuring faster access to potentially life-saving medications without unnecessary bureaucratic hurdles. The law applies only to drugs approved by the FDA and consistent with evidence-based cancer treatment protocols.
SB 537 revises Montana's marijuana tax revenue distribution, directing funds from the marijuana state special revenue account to new and existing state accounts. It requires transferring excess funds annually to specific accounts, including 12% to the HEART account for addiction treatment and mental health programs, 20% to wildlife habitat projects, and 14% to behavioral health initiatives. The bill also allocates funds for law enforcement canine training, sexual assault evidence kits, and homeless shelter support, while modifying existing transfer rules for agencies like the Department of Fish, Wildlife, and Parks. These changes apply to all state agencies receiving marijuana tax revenue under Montana law.
House Bill 565, also known as the "Building Families Act," would have required certain health insurance policies in Montana to cover the diagnosis and treatment of infertility, including in vitro fertilization (IVF). This mandate would have applied to small group, large group, and individual health insurance policies issued or renewed in the state. The bill defined infertility based on factors like age and time trying to conceive, or a physician's findings. It set a lifetime coverage minimum of at least $40,000 for fertilization services and aimed to ensure fertility coverage was not subject to different limitations than other medical benefits.
HB 273, the "Montana Medical Debt Patient Protection Act," aimed to limit how health care providers and third-party collectors pursue medical debt from patients in Montana. The bill would have prohibited certain collection actions, including wage garnishment, placing liens on a patient's primary residence, and reporting adverse information to credit agencies. It also mandated a 180-day waiting period after the first bill before "extraordinary collection actions," such as filing lawsuits or selling debt, could begin, along with requiring a 30-day notice to the patient. Additionally, it sought to provide patients with an opportunity to appeal insurance decisions before a bill went to collections.
HB 885 aims to improve customer service for Medicaid applicants and recipients in Montana. It requires the Department of Public Health and Human Services (DPHHS) to implement mobile-first technology for online applications and renewals, utilize text and email for communications, and ensure written notices are in plain language and translated. The bill also mandates the DPHHS to provide expected wait times and callback options for hotline callers and to reopen 10 local public assistance offices by June 30, 2026. Additionally, it establishes quarterly reporting requirements to the legislature on various Medicaid client service metrics.
HB 526 proposes that the state join the Advanced Practice Registered Nurse (APRN) compact. This initiative allows Advanced Practice Registered Nurses licensed in one member state to practice in other compact states without needing to obtain a separate license for each. The bill establishes a framework for uniform licensure requirements and facilitates the exchange of information between states for regulatory and enforcement purposes. Its aim is to streamline the licensing process for APRNs and enhance their ability to provide care across state lines, potentially increasing access to healthcare services.
HB 807 amends state law to prohibit individuals from being required to receive certain vaccines. Specifically, it mandates that vaccines whose use is allowed under an emergency use authorization (EUA) or those still undergoing safety trials cannot be a requirement. This applies to persons, governmental entities, employers, and public accommodations, preventing them from denying services, employment, or access based on non-receipt of such vaccines. The bill integrates this new prohibition into existing law concerning discrimination based on vaccination status.
HB 687 revises the age range for expanded Medicaid participants who are required to engage in community engagement activities. Previously, participants aged 19 to 55 were subject to this requirement. This bill extends that upper age limit, now requiring individuals from 19 to 62 years old to participate. Affected participants must complete 80 hours per month in activities such as employment, education, work training, or community service, unless they qualify for an exemption. This change directly impacts expanded Medicaid recipients between the ages of 56 and 62.
Senate Bill 495 eliminates the Tobacco Prevention Advisory Board. The bill repeals the specific section of law that established this board. It also amends existing statute to remove the board from the list of entities funded by state special revenue accounts, which are primarily used for tobacco disease prevention programs and the Children's Health Insurance Program. The direct effect is the dissolution of the advisory board, which previously provided guidance for these programs.
HB 41 adds gabapentin to Montana's Schedule V list of controlled substances under the "depressants" category. This change directly affects medical providers who prescribe gabapentin (used for nerve pain, seizures, and other conditions), pharmacists who dispense it, and patients using the medication. The bill amends Montana Code § 50-32-232 to explicitly include gabapentin - identified by its chemical name "1-(aminomethyl)cyclohexaneacetic acid" - in Schedule V depressants alongside drugs like pregabalin. This policy update standardizes gabapentin's regulatory classification without altering its medical use or prescribing rules.